Search result for "tecentriq"
Approximately 9 trademarks found.
TECENTRIQ
Pharmaceutical oncology preparations
Current Owner: GENENTECH, INC.
Status: SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED
Filed on: 2014-10-31
TECENTRIQ HYBREZA
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Current Owner: Genentech, Inc.
Status: NOTICE OF ALLOWANCE - ISSUED
Filed on: 2022-03-30
TECENTRIQ HYQEVO
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Current Owner: Genentech, Inc.
Status: NOTICE OF ALLOWANCE - ISSUED
Filed on: 2022-03-30
TECENTRIQ HYBREZA
Education services, namely, providing courses, presentations, brochures, and training, in the field of oncology, autoimmune, or inflammatory diseases...
Current Owner: Genentech, Inc.
Status: NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Filed on: 2023-05-18
TECENTRIQ HYWIK
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Current Owner: Genentech, Inc.
Status: NOTICE OF ALLOWANCE - ISSUED
Filed on: 2022-03-30
TECENTRIQ HYVELO
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Current Owner: Genentech, Inc.
Status: NOTICE OF ALLOWANCE - ISSUED
Filed on: 2022-03-30
TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG
Providing online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to...
Current Owner: Genentech, Inc.
Status: REGISTERED
Filed on: 2020-11-13
TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG
Providing online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to...
Current Owner: GENENTECH, INC.
Status: ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Filed on: 2016-09-21
TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG
Pharmaceutical oncology preparations
Current Owner: GENENTECH, INC.
Status: ABANDONED - EXPRESS
Filed on: 2015-12-16
